🎯 check Abemaciclib (LY2835219) product page
Abemaciclib is an ATP-competitive CDK4/6 inhibitor. It blocks Rb signaling by reducing Rb phosphorylation, halting cell growth.
Abemaciclib (LY2835219) Mechanism of Action: CDK4/6 Inhibition in Breast Cancer Cell Research
Abemaciclib (LY2835219) MOA：Targeting CDK4/6 / Rb-E2F Pathway for Early and Metastatic Breast Cancer